Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subconjunctival bevacizumab versus placebo for acquired corneal opacity with corneal neovascularization
PACTR202509763211872Phase 3Not yet recruiting
- Sponsor
- Abeona Therapeutics Inc.
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab in corneal fibrosis and corneal neovascularization (CNV), sponsored by Abeona Therapeutics Inc. Primary endpoints: Corneal surface area covered by opacity and Corneal neovascularization extent. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
corneal fibrosiscorneal neovascularization (CNV)
Beyond the preview
Go deeper on PACTR202509763211872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202509763211872.